前体mRNA 通过选择性剪接产生不同异构体进而影响其蛋白产物的结构、功能和表达水平，剪接因子在这个过程中发挥着重要调节作用。异常选择性剪接事件与剪接因子水平都与癌症的发生发展过程相关，许多基因的剪接异构体和剪接因子本身已被确定为肿瘤标记物和治疗靶向。内膜癌复发率高，目前尚缺乏有效预后因子来指导临床治疗。前期回顾性研究表明剪接因子YT521可能被确立为内膜癌独立的预后因子。本项目进一步研究YT521在内膜癌中的临床意义、作用目标和调节机制，并通过外显子芯片在基因组范围内筛查内膜癌中特异的选择性剪接事件，为内膜癌提供新的诊断标记物和治疗靶向，有助于进一步理解内膜癌发生发展过程中的分子机制，具有重要的临床实践和理论指导意义。

The alternative splicing of pre-mRNA will generate protein isoforms with distinct structures, functions and expressing levels. Splicing factors are important regulators in this process. Abnormality of splicing events and splicing factors exert significant impacts on tumorigenesis and many of them are convinced as tumor biomarker or therapeutic targets. Endometrial cancer (EC) which is one of the most common female malignances and has a high recurrence rate is still in demand of effective prognostic factors to optimize its clinical interventions. The splicing factor YT521 might play a role as independent prognostic factor in EC according to previous regressive research. In this project the clinical implications, targets and mechanisms of YT521 in EC will be further studied. Moreover the specific splicing events in EC will be genome-wide identified through exon-arrays, so as to pick out the potential diagnostic marker and therapeutic targets of EC. Taken together this project will contribute to comprehensively understand the underlying molecular mechanisms of tumorigenesis and possess a profound significance in both clinical and theoretical levels.